Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 3/20 | 0.52 |
| ▸ | CNR2 | P34972 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.51 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273212 | 0.90 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL26602804 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL369084 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL369798 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL369784 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL371275 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL371296 | 0.90 | PRKCA (0.60) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL27546892 | 0.85 | PRKCA (0.55) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL16612104 | 0.82 | PRKCA (0.68) | PRKCAPRKCEPRKCQPRKCDCNR1 | |
| SCHEMBL2348523 | 0.82 | DGKA (0.57) | PRKCAPRKCEPRKCQPRKCDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| CN-117377499-A | Extracellular vesicles linked to bioactive molecules via optimized linkers and anchoring moieties | 隆萨销售股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9040492-B2 | Double-stranded lipid-modified RNA having high RNA interference effect | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264167-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | National Institute of Advanced Industrial Science and Technology (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | PRKCA 3218/4885PRKCE 3416/4885PRKCQ 3613/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | PRKCA 3218/4885PRKCE 3416/4885PRKCQ 3613/4885 |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | NSUN3, NSUN2, ADAR | PRKCA 3648/4885PRKCE 4530/4885PRKCQ 3739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.